A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis (BLUEPRINT)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety, and Tolerability of BLU-5937 for the Treatment of Chronic Pruritus in Adult Subjects With Atopic Dermatitis
Sponsor: Bellus Health Inc. - a GSK company
A PHASE2 clinical study on Atopic Dermatitis and Chronic Pruritus, this trial is completed. The trial is conducted by Bellus Health Inc. - a GSK company and has accumulated 9 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jan 2024 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2022 — Nov 2022 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Oct 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Apr 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Apr 2021 [monthly]
Recruiting PHASE2
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bellus Health Inc. - a GSK company
For direct contact, visit the study record on ClinicalTrials.gov .